American Society of Hematology

The Hematologist: ASH News and Reports, the Society's member newsletter, is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

H3K27 Demethylases: A New Therapeutic Target in T-ALL?

Dr. Raetz discusses novel therapeutic approaches for the treatment of T-ALL.

Read more

JAK Inhibitors: Life is Good, Stable is Good

Dr. Verstovsek discusses the benefits of treatment with JAK inhibitors.

Read more

Can Prolyl Hydroxylase Inhibition Treat EPO-Deficient Anemia of Renal Failure?

Dr. Koury evaluates the safety and efficacy of Roxadustat in the treatment of anemia.

Read more

Presidents Column

Dr_ David A_ Williams - Presidents Column

David A. Williams, MD

Chief of Hematology/Oncology; Director of Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts
Earnest Support for Careers and Cures
February 24, 2015

Dr. Williams shines a spotlight on the scholarships and awards ASH makes possible each year, and the successes of the numerous winners.

View All

Clinical Trials Corner

Can Prolyl Hydroxylase Inhibition Treat EPO-Deficient Anemia of Renal Failure With Fewer Vascular Complications Than EPO Itself?
February 12, 2015

Dr. Koury evaluates the safety and efficacy of Roxadustat in the treatment of anemia in dialysis patients.

View All

Ask The Hematologist

Ask the Hematologists: Treatment of Castleman Disease
February 27, 2015

Dr. Frits van Rhee and Dr. David Fajgenbaum discuss different treatment approaches to Castleman disease with the advent of anti-interleukin-6 therapy.

View All

Mini Review

Labile Iron: Potential Toxicity in Iron Overload Disorders
February 13, 2015

Dr. Cabantchik and Dr. Rachmilewitz talk about potential toxicity in Iron Overload Disorder caused by labile cell iron or labile iron pool.

View All

Op Ed

Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?”
November 19, 2014

Dr. Alexis Thompson makes a thorough assessment of the latest clinical practice guidelines for sickle cell disease.

View All
  • New SGR Bill Released

    On March 19, the House of Representatives introduced a bill that would permanently address the SGR issue.  This bill largely follows the policy of the bill that was introduced by the committees of jurisdiction during the last Congress.  That bill, which ASH supported, eliminated the SGR update formula in favor of a new payment schedule.  Follow the link above to read more about the bill.

  • New Oncology Care Model Released by Center for Medicare and Medicaid Innovation

    On February 12, 2015, the Center for Medicare and Medicaid Innovation (CMMI) revealed the opportunity for practices to participate in a payment model dedicated the care of patients with cancer.  Although there will be additional details to finalize, CMMI would like practices to express interest in participating in the model by April 23, 2015, even though it will not begin paying with this method until 2016.  Click on the headline to read more.

  • ASH Comments on FDA Draft Guidance for Laboratory Developed Tests

    On January 30, ASH submitted comments on the Food and Drug Administration's (FDA) Draft Guidance  on Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).  The Guidance Document proposes that FDA assert its regulatory authority and increase oversight of LDTs.  Click on the link above to read more about ASH's comments.

  • ASH Comments on NIH Single IRB Policy

    On January 28, The American Society of Hematology (ASH) submitted comments  on the National Institutes of Health's (NIH) Draft Policy to promote the use of a single Institutional Review Board (IRB) of record for domestic sites of multi-site clinical studies funded by NIH.  The draft NIH policy proposes that all NIH-funded, multi-site studies carried out in the United States, whether supported through grants, contracts, or the NIH intramural program, should use a single IRB.  Read more to learn about ASH's stance on the policy.

View all policy news
back to top